The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome

Juthamas Wirojanan, Sebastien Jacquemont, Rafael Diaz, Susan Bacalman, Thomas F. Anders, Randi J Hagerman, Beth L. Goodlin-Jones

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Study Objective: To determine the efficacy of melatonin on sleep problems in children with autistic spectrum disorder (ASD) and fragile X syndrome (FXS). Methods: A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted following a 1-week baseline period. Either melatonin, 3 mg, or placebo was given to participants for 2 weeks and then alternated for another 2 weeks. Sleep variables, including sleep duration, sleep-onset time, sleep-onset latency time, and the number of night awakenings, were recorded using an Actiwatch and from sleep diaries completed by parents. All participants had been thoroughly assessed for ASD and also had DNA testing for the diagnosis of FXS. Results: Data were successfully obtained from the 12 of 18 subjects who completed the study (11 males, age range 2 to 15.25 years, mean 5.47, SD 3.6). Five participants met diagnostic criteria for ASD, 3 for FXS alone, 3 for FXS and ASD, and 1 for fragile X premutation. Eight out of 12 had melatonin first. The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02). Conclusion: The results of this study support the efficacy and tolerability of melatonin treatment for sleep problems in children with ASD and FXS.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalJournal of Clinical Sleep Medicine
Volume5
Issue number2
StatePublished - Apr 15 2009

Fingerprint

Fragile X Syndrome
Melatonin
Autistic Disorder
Sleep
Placebos
Cross-Over Studies
Parents

Keywords

  • Autism
  • Fragile X syndrome
  • Melatonin
  • Sleep problem

ASJC Scopus subject areas

  • Clinical Neurology
  • Pulmonary and Respiratory Medicine
  • Neurology

Cite this

Wirojanan, J., Jacquemont, S., Diaz, R., Bacalman, S., Anders, T. F., Hagerman, R. J., & Goodlin-Jones, B. L. (2009). The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. Journal of Clinical Sleep Medicine, 5(2), 145-150.

The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. / Wirojanan, Juthamas; Jacquemont, Sebastien; Diaz, Rafael; Bacalman, Susan; Anders, Thomas F.; Hagerman, Randi J; Goodlin-Jones, Beth L.

In: Journal of Clinical Sleep Medicine, Vol. 5, No. 2, 15.04.2009, p. 145-150.

Research output: Contribution to journalArticle

Wirojanan, J, Jacquemont, S, Diaz, R, Bacalman, S, Anders, TF, Hagerman, RJ & Goodlin-Jones, BL 2009, 'The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome', Journal of Clinical Sleep Medicine, vol. 5, no. 2, pp. 145-150.
Wirojanan, Juthamas ; Jacquemont, Sebastien ; Diaz, Rafael ; Bacalman, Susan ; Anders, Thomas F. ; Hagerman, Randi J ; Goodlin-Jones, Beth L. / The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. In: Journal of Clinical Sleep Medicine. 2009 ; Vol. 5, No. 2. pp. 145-150.
@article{758da58271804b15b7907c0e596aedf9,
title = "The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome",
abstract = "Study Objective: To determine the efficacy of melatonin on sleep problems in children with autistic spectrum disorder (ASD) and fragile X syndrome (FXS). Methods: A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted following a 1-week baseline period. Either melatonin, 3 mg, or placebo was given to participants for 2 weeks and then alternated for another 2 weeks. Sleep variables, including sleep duration, sleep-onset time, sleep-onset latency time, and the number of night awakenings, were recorded using an Actiwatch and from sleep diaries completed by parents. All participants had been thoroughly assessed for ASD and also had DNA testing for the diagnosis of FXS. Results: Data were successfully obtained from the 12 of 18 subjects who completed the study (11 males, age range 2 to 15.25 years, mean 5.47, SD 3.6). Five participants met diagnostic criteria for ASD, 3 for FXS alone, 3 for FXS and ASD, and 1 for fragile X premutation. Eight out of 12 had melatonin first. The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02). Conclusion: The results of this study support the efficacy and tolerability of melatonin treatment for sleep problems in children with ASD and FXS.",
keywords = "Autism, Fragile X syndrome, Melatonin, Sleep problem",
author = "Juthamas Wirojanan and Sebastien Jacquemont and Rafael Diaz and Susan Bacalman and Anders, {Thomas F.} and Hagerman, {Randi J} and Goodlin-Jones, {Beth L.}",
year = "2009",
month = "4",
day = "15",
language = "English (US)",
volume = "5",
pages = "145--150",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "2",

}

TY - JOUR

T1 - The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome

AU - Wirojanan, Juthamas

AU - Jacquemont, Sebastien

AU - Diaz, Rafael

AU - Bacalman, Susan

AU - Anders, Thomas F.

AU - Hagerman, Randi J

AU - Goodlin-Jones, Beth L.

PY - 2009/4/15

Y1 - 2009/4/15

N2 - Study Objective: To determine the efficacy of melatonin on sleep problems in children with autistic spectrum disorder (ASD) and fragile X syndrome (FXS). Methods: A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted following a 1-week baseline period. Either melatonin, 3 mg, or placebo was given to participants for 2 weeks and then alternated for another 2 weeks. Sleep variables, including sleep duration, sleep-onset time, sleep-onset latency time, and the number of night awakenings, were recorded using an Actiwatch and from sleep diaries completed by parents. All participants had been thoroughly assessed for ASD and also had DNA testing for the diagnosis of FXS. Results: Data were successfully obtained from the 12 of 18 subjects who completed the study (11 males, age range 2 to 15.25 years, mean 5.47, SD 3.6). Five participants met diagnostic criteria for ASD, 3 for FXS alone, 3 for FXS and ASD, and 1 for fragile X premutation. Eight out of 12 had melatonin first. The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02). Conclusion: The results of this study support the efficacy and tolerability of melatonin treatment for sleep problems in children with ASD and FXS.

AB - Study Objective: To determine the efficacy of melatonin on sleep problems in children with autistic spectrum disorder (ASD) and fragile X syndrome (FXS). Methods: A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted following a 1-week baseline period. Either melatonin, 3 mg, or placebo was given to participants for 2 weeks and then alternated for another 2 weeks. Sleep variables, including sleep duration, sleep-onset time, sleep-onset latency time, and the number of night awakenings, were recorded using an Actiwatch and from sleep diaries completed by parents. All participants had been thoroughly assessed for ASD and also had DNA testing for the diagnosis of FXS. Results: Data were successfully obtained from the 12 of 18 subjects who completed the study (11 males, age range 2 to 15.25 years, mean 5.47, SD 3.6). Five participants met diagnostic criteria for ASD, 3 for FXS alone, 3 for FXS and ASD, and 1 for fragile X premutation. Eight out of 12 had melatonin first. The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02). Conclusion: The results of this study support the efficacy and tolerability of melatonin treatment for sleep problems in children with ASD and FXS.

KW - Autism

KW - Fragile X syndrome

KW - Melatonin

KW - Sleep problem

UR - http://www.scopus.com/inward/record.url?scp=65349169040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349169040&partnerID=8YFLogxK

M3 - Article

C2 - 19968048

AN - SCOPUS:65349169040

VL - 5

SP - 145

EP - 150

JO - Journal of Clinical Sleep Medicine

JF - Journal of Clinical Sleep Medicine

SN - 1550-9389

IS - 2

ER -